sPRAVATO®

Request an Appointment
+1 281-554-0123

SPRAVATO® (Esketamine) for Depression

Advanced Treatment for Treatment-Resistant Depression at Family Psychiatry

Family Psychiatry offers SPRAVATO® (esketamine) nasal spray, an FDA-approved treatment for adults with treatment-resistant depression (TRD) and for those with major depressive disorder (MDD) with acute suicidal thoughts or behaviors.

SPRAVATO® provides a rapid-acting, evidence-based option for patients who have not responded adequately to traditional antidepressant medications.

What Is SPRAVATO®?

SPRAVATO® is a prescription nasal spray medication containing esketamine, a compound related to ketamine. Unlike standard antidepressants that primarily affect serotonin or norepinephrine, SPRAVATO® works on the brain’s glutamate system, targeting NMDA receptors involved in mood regulation.

This unique mechanism allows SPRAVATO® to help relieve depressive symptoms more quickly than traditional antidepressants for some patients.

What Conditions Does SPRAVATO® Treat?

SPRAVATO® is FDA-approved for adults with:

  • Treatment-Resistant Depression (TRD)
    Depression that has not improved despite trying two or more antidepressant medications

  • Major Depressive Disorder (MDD) with acute suicidal thoughts or behaviors, when used in combination with an oral antidepressant

How Does SPRAVATO® Treatment Work?

SPRAVATO® is administered only in a certified medical office under close supervision.

What to Expect:

  • The medication is self-administered as a nasal spray under provider guidance

  • Patients are monitored for at least two hours after each treatment

  • Treatments are typically given twice weekly during the initial phase, then less frequently over time

  • Patients must arrange transportation home and should not drive until the following day

SPRAVATO® is used in combination with an oral antidepressant, not as a standalone treatment.

Is SPRAVATO® Safe?

SPRAVATO® is considered safe and effective when used as directed under medical supervision. Because of potential side effects, it is available only through a Risk Evaluation and Mitigation Strategy (REMS) program.

Possible Side Effects May Include:

  • Dissociation (feeling detached or “spaced out”)

  • Dizziness or nausea

  • Sedation or sleepiness

  • Temporary increase in blood pressure

These effects typically occur shortly after dosing and resolve within the monitoring period.

Does SPRAVATO® Work?

Clinical studies show that SPRAVATO® can significantly reduce depressive symptoms in adults with treatment-resistant depression, sometimes within hours to days rather than weeks.

While response varies by individual, many patients experience:

  • Rapid symptom relief

  • Improved mood and functioning

  • Reduced suicidal thinking when used appropriately

As with all depression treatments, individual results may vary, and ongoing follow-up care is essential.

Everything You Need To Know About Spravato®

spravato_logo_r_c3_color_rgb-2.png

SPRAVATO® (esketamine) nasal spray is a rapid-acting, FDA-approved treatment for adults with treatment-resistant depression (TRD) and for those with major depressive disorder (MDD) with acute suicidal ideation or behavior.

With thousands of patients treated under strict medical supervision, SPRAVATO® is providing new hope for individuals living with depression, helping many achieve meaningful improvement in mood and overall functioning.

Frequently Asked Questions:

  • SPRAVATO® has been shown to rapidly reduce depressive symptoms in adults with treatment-resistant depression (TRD) and in those with MDD with acute suicidal thoughts, often within hours to days when combined with an oral antidepressant. Individual results may vary.

  • SPRAVATO® may be an option if you have not responded to at least two antidepressant medications or are experiencing severe depressive symptoms. A qualified provider at Family Psychiatry will determine if it is appropriate for your condition.

  • Treatment schedules are personalized. Typically, the initial phase includes twice-weekly sessions, followed by less frequent maintenance treatments. The total duration depends on your response and treatment plan.

  • Many patients notice improvements within hours to days of treatment. Full benefits may require multiple sessions in combination with an oral antidepressant.

  • Many insurance plans, including Medicare and commercial carriers, may cover SPRAVATO® for eligible patients. Coverage varies, and our team can assist with verification and prior authorization.

Important Safety Information:

SPRAVATO® is available by prescription only and must be administered in a certified healthcare setting. Patients are monitored after each treatment due to risks of sedation, dissociation, and increased blood pressure. SPRAVATO® is not appropriate for everyone.

Your provider will determine whether this treatment is suitable based on your medical history and current condition.

SPRAVATO® Is Indicated For:

  • Treatment-Resistant Depression (TRD) in adults

  • Depressive symptoms in adults with Major Depressive Disorder (MDD) who experience acute suicidal ideation or behavior

SPRAVATO® must be administered in a certified healthcare setting under medical supervision as part of a federally required safety program.

For additional prescribing and safety information, visit:
👉 www.SPRAVATOrems.com